D-Index & Metrics Best Publications

Raymond Alexanian

The University of Texas MD Anderson Cancer Center
United States

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 85 Citations 30,059 223 World Ranking 9496 National Ranking 5030

Overview

What is he best known for?

The fields of study Raymond Alexanian is best known for:

Chemotherapy
Multiple myeloma
Leukemia

His Plasma cell neoplasm research extends to the thematically linked field of Multiple myeloma. As part of his studies on Plasma cell neoplasm, he frequently links adjacent subjects like Plasmacytoma. Raymond Alexanian integrates Plasmacytoma and Myeloma protein in his studies. While working in this field, Raymond Alexanian studies both Myeloma protein and Multiple myeloma. Many of his studies on Internal medicine apply to Complete response as well. He conducted interdisciplinary study in his works that combined Chemotherapy and Clinical trial. As part of his studies on Gastroenterology, Raymond Alexanian frequently links adjacent subjects like Prednisone. Raymond Alexanian merges Surgery with Radiation therapy in his research. Raymond Alexanian merges many fields, such as Radiation therapy and Surgery, in his writings.

His most cited work include:

International uniform response criteria for multiple myeloma (2267 citations)
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma (681 citations)
Plasma cell myeloma--new biological insights and advances in therapy (215 citations)

What are the main themes of his work throughout his whole career to date

Part of his project on Cyclophosphamide includes research on Vincristine and ThioTEPA. Raymond Alexanian integrates many fields, such as Immunology, Antibody and Biochemistry, in his works. With his scientific publications, his incorporates both Biochemistry and Immunology. Raymond Alexanian performs multidisciplinary study on Multiple myeloma and ThioTEPA in his works. Internal medicine and Melphalan are commonly linked in his work. Raymond Alexanian merges many fields, such as Melphalan and Cyclophosphamide, in his writings. His multidisciplinary approach integrates Chemotherapy and Vincristine in his work. His study in Prednisone extends to Gastroenterology with its themes. His work in Prednisone is not limited to one particular discipline; it also encompasses Gastroenterology.

Raymond Alexanian most often published in these fields:

Multiple myeloma (90.48%)
Internal medicine (87.30%)
Chemotherapy (55.56%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Paul G. Richardson;Bart Barlogie;James Berenson;Seema Singhal.
The New England Journal of Medicine (2003)

3317 Citations

International uniform response criteria for multiple myeloma

B. G. M. Durie;J.-L. Harousseau;J. S. Miguel;J. Blade.
Leukemia (2006)

3186 Citations

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

S. Jagannath;B. Barlogie;J. Berenson;D. Siegel.
British Journal of Haematology (2004)

960 Citations

Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating Agents

Bart Barlogie;Lon Smith;Raymond Alexanian.
The New England Journal of Medicine (1984)

944 Citations

Thalidomide Alone or With Dexamethasone for Previously Untreated Multiple Myeloma

Donna M Weber;Kim Rankin;Maria Gavino;Kay Delasalle.
Journal of Clinical Oncology (2003)

804 Citations

Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens.

Raymond Alexanian;Arthur Haut;Asad U. Khan;Montague Lane.
JAMA (1969)

787 Citations

Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib

Paul G. Richardson;Hannah Briemberg;Sundar Jagannath;Patrick Y. Wen.
Journal of Clinical Oncology (2006)

748 Citations

Leukocyte Interferon-Induced Tumor Regression in Human Metastatic Breast Cancer, Multiple Myeloma, and Malignant Lymphoma

Jordan U. Gutterman;George R. Blumenschein;Raymond Alexanian;Hwee-Yong Yap.
Annals of Internal Medicine (1980)

744 Citations

The Treatment of Multiple Myeloma

Raymond Alexanian;Meletios Dimopoulos.
The New England Journal of Medicine (1994)

538 Citations

Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients.

Jordan U. Gutterman;Seymour Fine;Jorge Quesada;Sandra J. Horning.
Annals of Internal Medicine (1982)

534 Citations

If you think any of the details on this page are incorrect, let us know.

Frequent Co-Authors

External Links

Personal Website for Raymond Alexanian